Monocarboxylic Acid Buffer for Antibody Conjugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody purification methods require dialysis steps to remove interfering buffer components, which are time-consuming, costly, and result in material losses, as conventional buffers used in purification interfere with subsequent conjugation reactions.
Innovation Solution
A conjugation-friendly elution buffer (CFEB) system using a monocarboxylic acid buffer compound with an amine substituent at the alpha or beta position, such as glycine betaine, that allows for antibody purification and conjugation without the need for dialysis, by minimizing interference in carbodiimide, NHS ester, and other common conjugation chemistries.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional buffers (glycine, citric acid) are used for antibody elution, then elution efficiency is improved, but interference with subsequent conjugation reactions occurs
Solution Approach 1:
The patent changes the chemical parameters of the elution buffer by using monocarboxylic acid buffers (acetic acid, propionic acid, butyric acid) instead of conventional buffers like glycine or citric acid. These alternative buffers maintain effective elution capability while having minimal interference with carbodiimide and NHS ester conjugation reactions, thus resolving the contradiction between elution efficiency and conjugation compatibility.
Solution Approach 2:
The patent employs a simple, inexpensive buffer system that can be directly used without requiring subsequent dialysis or buffer exchange steps. The monocarboxylic acid buffers are cheap, easily prepared, and their temporary presence in the antibody solution does not harm the final conjugation product, effectively making the buffer a disposable component that serves its elution function and then exits the process without causing harm.
2Object-generated harmful factors
If dialysis is performed to remove buffer components, then interference with conjugation is reduced, but time consumption and material loss increase
Solution Approach 1:
The patent extracts or removes the problematic buffer components (glycine, citric acid) from the elution process and replaces them with compatible monocarboxylic acid buffers. This extraction of harmful substances eliminates the need for dialysis to remove interfering buffer components, thus saving time and preventing antibody material loss while still achieving effective elution.
Solution Approach 2:
The patent performs preliminary action by selecting elution buffers that are inherently compatible with subsequent conjugation reactions. By choosing monocarboxylic acid buffers from the outset, the process prevents the formation of harmful buffer-conjugation interactions before they can occur, eliminating the need for subsequent dialysis or buffer exchange steps.
3Object-generated harmful factors
If dialysis is performed to remove buffer components, then interference with conjugation is reduced, but production cost increases
Solution Approach 1:
The patent uses inexpensive monocarboxylic acid buffers that serve their elution function and then can be simply diluted or removed without requiring expensive dialysis equipment or additional purification steps. The buffers themselves are cheap chemical substances (acetic acid, propionic acid, etc.) that do not require recovery or special handling, thereby reducing production costs while eliminating buffer interference.
Solution Approach 2:
The monocarboxylic acid buffers serve multiple functions: they effectively elute antibodies from the affinity column and simultaneously are compatible with subsequent conjugation reactions. This dual functionality eliminates the need for separate dialysis or buffer exchange steps, simplifying the overall process and reducing production costs associated with additional equipment, time, and materials.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables efficient antibody conjugation without pre-conjugation dialysis, reducing material loss and production costs, while maintaining the stability and specificity of the antibody, allowing for direct use in various conjugation reactions without buffer exchange.
Implementation Method 1
minimizing interference in carbodiimide, NHS ester, and other common conjugation chemistries
Implementation Method 2
minimizing interference in carbodiimide, NHS ester, and other common conjugation chemistries
Implementation Method 3
maintaining the stability and specificity of the antibody
Data Source
AI summary
A method for conjugating an isolated antibody to a label or derivatisation reagent, which method comprises contacting the antibody with an activated label or activated derivatisation reagent, or contacting the antibody with the label or derivatisation reagent in the presence of an antibody conjugation reagent, in a buffer system which comprises a monocarboxylic acid buffer compound other than glycine, bearing an amine substituent at the alpha or beta position.